Literature DB >> 8954019

Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine.

B Biondi1, S Fazio, A Cuocolo, D Sabatini, E Nicolai, G Lombardi, M Salvatore, L Saccà.   

Abstract

To assess cardiac function and exercise tolerance in patients receiving long term TSH-suppressive therapy with levothyroxine (L-T4), we studied maximal exercise capacity with a bicycle ergometer and left ventricular function at rest and during physical exercise by radionuclide angiography. The evaluation was performed in 10 patients receiving L-T4 therapy (2.31 +/- 0.13 microgram/kg) for 5-9 yr, presenting with effort dyspnea and symptoms of adrenergic overactivity, and 10 matched control subjects. The patients were reassessed after 4 months of administration of the selective beta-adrenergic blocker bisoprolol (4.25 +/- 0.4 mg/day); L-T4 therapy remained unchanged. The results showed that at rest, left ventricular diastolic filling was impaired in the patients (P < 0.05), whereas systolic function was unaltered. During submaximal physical exercise, left ventricular ejection fraction increased in the controls from 58 +/- 2% to 65 +/- 2% (P < 0.001), whereas in the patients it fell from 63 +/- 2% to 53 +/- 2% (P < 0.01), mainly because of increased end-systolic left ventricular volume (P < 0.05). Exercise capacity was markedly reduced in the patients in terms of both peak workload (P < 0.001) and exercise duration (P < 0.001). beta-Adrenergic blockade prevented both the fall in ejection fraction and the increase in end-systolic volume during exercise, and improved exercise tolerance. In conclusion, our data show that long term TSH-suppressive therapy with L-T4 is not as harmless as believed, because it may cause marked impairment of cardiac functional reserve and physical exercise capacity. Administration of a beta-blocking drug for 4 months caused significant improvement of cardiac performance and exercise tolerance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8954019     DOI: 10.1210/jcem.81.12.8954019

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

Review 1.  The management of metastatic differentiated thyroid carcinoma.

Authors:  S I Sherman
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

Review 2.  Thyroid disease and the heart.

Authors:  A D Toft; N A Boon
Journal:  Heart       Date:  2000-10       Impact factor: 5.994

Review 3.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

Review 4.  Thyroid hormone therapy in differentiated thyroid cancer.

Authors:  Giorgio Grani; Valeria Ramundo; Antonella Verrienti; Marialuisa Sponziello; Cosimo Durante
Journal:  Endocrine       Date:  2019-10-15       Impact factor: 3.633

5.  Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.

Authors:  Aubrey A Carhill; Danielle R Litofsky; Douglas S Ross; Jacqueline Jonklaas; David S Cooper; James D Brierley; Paul W Ladenson; Kenneth B Ain; Henry G Fein; Bryan R Haugen; James Magner; Monica C Skarulis; David L Steward; Mingxhao Xing; Harry R Maxon; Steven I Sherman
Journal:  J Clin Endocrinol Metab       Date:  2015-07-14       Impact factor: 5.958

Review 6.  Subclinical hyperthyroidism: to treat or not to treat?

Authors:  E H Hoogendoorn; M den Heijer; A P J van Dijk; A R Hermus
Journal:  Postgrad Med J       Date:  2004-07       Impact factor: 2.401

7.  Subclinical hyperthyroidism and sport eligibility: an exploratory study on cardiovascular pre-participation screening in subjects treated with levothyroxine for multinodular goiter.

Authors:  L Di Luigi; A Parisi; F Quaranta; F Romanelli; E Tranchita; P Sgrò; P Nardi; G Fattorini; R Cavaliere; F Pigozzi; M D'Armiento; A Lenzi
Journal:  J Endocrinol Invest       Date:  2009-07-17       Impact factor: 4.256

8.  P wave duration and dispersion in patients with hyperthyroidism and the short-term effects of antithyroid treatment.

Authors:  Unal Guntekin; Yilmaz Gunes; Hakki Simsek; Mustafa Tuncer; Sevket Arslan
Journal:  Indian Pacing Electrophysiol J       Date:  2009-09-01

9.  Slow growth of benign thyroid nodules after menopause: no need for long-term thyroxine suppressive therapy in post-menopausal women.

Authors:  G Costante; U Crocetti; E Schifino; O Ludovico; C Capula; M Nicotera; F Arturi; S Filetti
Journal:  J Endocrinol Invest       Date:  2004-01       Impact factor: 4.256

10.  Levothyroxine therapy in preventing nodular recurrence after hemithyroidectomy: a retrospective study.

Authors:  M Alba; D Fintini; R M Lovicu; R M Paragliola; G Papi; C A Rota; A Pontecorvi; S M Corsello
Journal:  J Endocrinol Invest       Date:  2009-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.